Pilloxa, Chiesi enter digital collaboration for ultra-rare genetic disorder

"Digital health company Pilloxa announced Tuesday that it will collaborate with Chiesi Global Rare Diseases' Nordic office on using the Pilloxa platform to support the treatment journey for patients with nephropathic cystinosis across Scandinavia. "Together we are at the forefront of a new paradigm within personalised healthcare," remarked Pilloxa chief scientific officer Helena Rönnqvist, adding "we strongly believe that this will increase the quality of life for patients with [this condition]." Financial terms of the deal were not disclosed.

Pilloxa said that with a specially developed app, called Cool 2B Rare C, it aims to make patients with nephropathic cystinosis "take control of their disease" by helping them and their caregivers set medication reminders and follow adherence over time. The app also provides access to information about the disease and related topics. Brita Forsberg, medical advisor at Chiesi's Nordic office, noted that in developing the app, Pilloxa "interviewed patients, caregivers and physicians to get an insight on the gaps that need to be filled in order to improve the treatment journey."

Last year, Pilloxa received €580,000 ($703,000) in funding from the EU's EUROSTARS programme to develop a patient medication adherence system. This past January, it launched a study aimed at further validating its suite of medication support services, including an adherence app and digitally connected pillbox, to enable remote monitoring of patients newly diagnosed with atrial fibrillation.

..." Lire la suite